Elbert Chin

USPTO Granted Patents = 27 (Patent Applications = 14)

CIPO Patents = 1

EPO Patents = 11 (Patent Applications = 20)

Average Co-Inventor Count = 8.6

ph-index = 5

Forward Citations = 80(Granted Patents)

Location History:

San Jose, CA (US) (2011 - 2012)
San Mateo, CA (US) (2017 - 2024)

Company Filing History:

20 out of 919

Gilead Sciences, Inc.

patents

4 out of 4,942

Hoffmann-la Roche Inc.

Years Active: 2011-2025

Loading Chart...

27 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12479853 - HIV inhibitor compounds (2025-11-25),

2. 12448388 - PRMT5 inhibitors and uses thereof (2025-10-21),

3. 12415808 - Pyrrolo[1,2-b]pyridazine derivatives (2025-09-16),

4. 12121511 - GLP-1R modulating compounds (2024-10-22),

5. 12084455 - HIV inhibitor compounds (2024-09-10),

6. 12060351 - Thiadiazole IRAK4 inhibitors (2024-08-13),

7. 12037340 - Pentacyclic derivatives as Zika virus inhibitors (2024-07-16),

8. 11858918 - GLP-1R modulating compounds (2024-01-02),

9. 11702414 - Thiadiazole IRAK4 inhibitors (2023-07-18),

10. 11702404 - GLP-1R modulating compounds (2023-07-18),

11. 11572362 - Pyrrolo[1,2-b]pyridazine derivatives (2023-02-07),

12. 11535622 - Pyrrolo[1,2-b] pyridazine derivatives (2022-12-27),

13. 11078208 - HIV inhibitor compounds (2021-08-03),

14. 11053250 - Pyrrolo[1,2-b]pyridazine derivatives (2021-07-06),

15. 11052087 - Anti-HIV compounds (2021-07-06),

Title: Elbert Chin: Innovator in Pharmaceutical Patents

Introduction

Elbert Chin is an accomplished inventor based in San Mateo, California, recognized for his significant contributions to the pharmaceutical industry through his extensive portfolio of patents. With a total of 21 patents to his name, Chin has been instrumental in developing innovative compounds used for treating various medical conditions.

Latest Patents

Among his latest patents, Elbert Chin has developed GLP-1R modulating compounds, which include GLP-1R agonists, alongside compositions, methods, and kits for practical application. These compounds are particularly promising for treating GLP-1R mediated diseases or conditions. Additionally, he has contributed to the invention of HIV inhibitor compounds, described by his novel compound of Formula I. These advancements underscore his dedication to addressing critical health issues through inventive solutions.

Career Highlights

Elbert Chin has had a diverse career with influential companies such as Gilead Sciences, Inc. and Hoffmann-La Roche Inc. His work in these organizations has allowed him to harness research and innovation, translating scientific findings into applicable treatments. His experience spans various aspects of drug development, reinforcing his status as a leading figure in the industry.

Collaborations

Throughout his career, Elbert Chin has collaborated with notable professionals including Zheng-Yu Yang and Jeromy J Cottell. These collaborations have played a vital role in developing innovative pharmaceutical solutions, enhancing the efficacy of his patented inventions.

Conclusion

Elbert Chin's contributions to the field of pharmaceutical inventions, bolstered by his 21 patents, position him as a key innovator in his industry. His latest work on GLP-1R modulating compounds and HIV inhibitors demonstrates his commitment to improving health outcomes and pushing the boundaries of medical science. As he continues his research and innovation journey, the impact of his work will undoubtedly resonate in healthcare for years to come.

This text is generated by artificial intelligence and may not be accurate.